“How come indications that are foreignly approved cannot be used in Korea?”
Patients have suffered from an incident where an indication was approved by the U.S. FDA, not in Korea. In other words, the rights to access new drugs have been restricted.
If myelodysplastic syndrome is not treated, that is, stem cell transplantation is the most recognized therapy that can alte...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
